================================================================================

                     U.S. SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

[ ]  Form 10-K  [ ]  Form 20-F  [ ]  Form 11-K  [X]  Form 10-Q  [ ]  Form N-SAR
[ ]  Form N-CSR

                        For Period Ended: March 31, 2008

- --------------------------------------------------------------------------------
Nothing in this form shall be construed to imply the Commission has verified any
information contained herein.
- --------------------------------------------------------------------------------

                          PART I REGISTRANT INFORMATION

- --------------------------------------------------------------------------------

                            Full Name of Registrant:

                          THOMAS PHARMACEUTICALS, Ltd.

      750 HIGHWAY 34, MATAWAN, NJ                                  07747
(Address of principal executive offices)                         (Zip Code)
- --------------------------------------------------------------------------------

PART II  RULES 12B-25(B) AND (C)

- --------------------------------------------------------------------------------
     (a)  The reasons described in reasonable detail in Part III of this form
          could not be eliminated without unreasonable effort or expense.

     (b)  The subject report on Form 10-Q will be filed on or before the fifth
          calendar day following the prescribed due date.

     (c)  Not applicable.
- --------------------------------------------------------------------------------

PART III  NARRATIVE

- --------------------------------------------------------------------------------
The Registrant has been unable to complete and file, when originally due, the
Quarterly Report on Form 10-Q as a result of delays in finalizing the financial
statements in time for the independent accountants to review the Quarterly
Report.
- --------------------------------------------------------------------------------

PART IV  OTHER INFORMATION

- --------------------------------------------------------------------------------
     (1) Name and telephone number of person to contact in regard to this
notification

     Lawrence A. Muenz                           (202) 728-2909
     -----------------                   ------------------------------
          (Name)                         (Area Code) (Telephone Number)

     (2) Have all other periodic reports required under section 13 or 15(d) of
the Securities Exchange Act of 1934 or section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for shorter period that the registrant
was required to file such report(s) been filed? If the answer is no, identify
report(s). [X] Yes [ ] No


     (3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof? [X]
Yes [X] No [ ]

     Total revenues for the three months ended March 31, 2008 and 2007 were $285
and $18,202, respectively. Net loss before preferred dividends for the three
months ended March 31, 2008 and 2007 were $186,893 and $337,253, respectively.


                          THOMAS PHARMACEUTICALS, Ltd.

has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.


Date: May 16, 2008                  By:    /s/ Mark Meller
                                           ----------------
                                    Name:  Mark Meller
                                           President and Chief Executive Officer